Allakos Inc.
ALLK evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ALLK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2025.
Tracking 1 pipeline candidate · 2 clinical trials for Allakos Inc..
Run Allakos Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Allakos Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
5.8 months
D/E 0.07
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Allakos Inc.'s lead drug candidate?
Allakos Inc.'s most advanced tracked candidate is ak006 (Phase 1) for Chronic spontaneous urticaria (CSU).
Who is the CEO of Allakos Inc.?
Robert Alexander, Ph.D. is the chief executive officer of Allakos Inc. (ALLK).
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.